Table 2.

Association between progression-free survival (PFS)/overall survival (OS)/disease control rate (DCR) and adverse events with consideration of a-priori covariates in regorafenib.

Regorafenib
Cox-Regression with Consideration of A-Priori Covariates	Nausea/Vertigo
	OS	PFS	DCR
	HR (95% CI); p-Value	HR (95% CI); p-Value	OR (95% CI); p-Value
Available Cases	n = 66	n = 53	n = 53
Yes vs.No	3.621 (1.519–8.630); 0.004	0.969 (0.387–2.428); 0.946	1.448 (0.361–5.809); 0.602
Age
	0.990 (0.950–1.031); 0.626	1.017 (0.981–1.055); 0.351	0.992 (0.934–1.053); 0.786
Sex
Female vs. Male	1.074 (0.444–2.599); 0.873	1.284 (0.531–3.109); 0.579	0.483 (0.133–1.749); 0.267
Ras-Gen-Status
Wildtyp vs. Mutant	2.175 (0.951–4.975); 0.066	2.197 (1.033–4.671); 0.041	0.374 (0.118–1.185); 0.095
Localization
Right vs. Left	0.845 (0.326–2.188); 0.729	1.083 (0.457–2.566); 0.857	1.043 (0.261–4.169); 0.953
Cox-Regression with Consideration of A-priori Covariates	Oral-Mucositis/Stomatitis
	OS	PFS	DCR
	HR (95% CI); p-Value	HR (95% CI); p-Value	OR (95% CI); p-Value
Available Cases	n = 66	n = 53	n = 53
Yes vs. No	2.484 (0.924–6.677); 0.071	3.258 (1.381–7.687); 0.007	0.071 (0.007–0.718); 0.025
Age
	0.999 (0.959–1.041); 0.956	1.026 (0.987–1.068); 0.197	0.978 (0.917–1.043); 0.493
Sex
Female vs. Male	0.902 (0.383–2.124); 0.813	1.428 (0.591–3.450); 0.429	0.349 (0.084–1.454); 0.148
Ras-Gen-Status
Wildtyp vs. Mutant	2.125 (0.909–4.966); 0.082	2.385 (1.113–5.113); 0.025	0.329 (0.095–1.144); 0.080
Localization
Right vs. Left	0.835 (0.320–2.177); 0.712	1.067 (0.447–2.548); 0.884	1.029 (0.243–4.363); 0.969

OS: overall survival, PFS: progression free survival, DCR: disease control rate, HR: hazard ratio, OR: odds ratio.